[go: up one dir, main page]

MX2014010481A - Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica. - Google Patents

Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.

Info

Publication number
MX2014010481A
MX2014010481A MX2014010481A MX2014010481A MX2014010481A MX 2014010481 A MX2014010481 A MX 2014010481A MX 2014010481 A MX2014010481 A MX 2014010481A MX 2014010481 A MX2014010481 A MX 2014010481A MX 2014010481 A MX2014010481 A MX 2014010481A
Authority
MX
Mexico
Prior art keywords
lateral sclerosis
amyotrophic lateral
new compositions
treating amyotrophic
treatment
Prior art date
Application number
MX2014010481A
Other languages
English (en)
Other versions
MX373763B (es
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Rodolphe Hajj
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/053570 external-priority patent/WO2012117076A2/en
Application filed by Pharnext filed Critical Pharnext
Publication of MX2014010481A publication Critical patent/MX2014010481A/es
Publication of MX373763B publication Critical patent/MX373763B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para el tratamiento de la esclerosis lateral amiotrófica. Más específicamente, la presente invención se refiere a nuevas terapias de combinación para el tratamiento de la esclerosis lateral amiotrófica o un trastorno relacionado.
MX2014010481A 2011-03-01 2013-02-28 Uso de una composición de combinación de acamprosato y baclofeno de liberación sostenida, para el tratamiento de esclerosis lateral amiotrófica. MX373763B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11305217 2011-03-01
PCT/EP2012/053565 WO2012117073A2 (en) 2011-03-01 2012-03-01 New compositions for treating neurological disorders
PCT/EP2012/053570 WO2012117076A2 (en) 2011-03-01 2012-03-01 Baclofen and acamprosate based therapy of neurogical disorders
PCT/EP2013/054024 WO2013127917A1 (en) 2011-03-01 2013-02-28 New compositions for treating amyotrophic lateral sclerosis

Publications (2)

Publication Number Publication Date
MX2014010481A true MX2014010481A (es) 2015-03-20
MX373763B MX373763B (es) 2020-03-24

Family

ID=44124101

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013010044A MX360871B (es) 2011-03-01 2012-03-01 Nuevas composiciones para tratar trastornos neurológicos.
MX2014010481A MX373763B (es) 2011-03-01 2013-02-28 Uso de una composición de combinación de acamprosato y baclofeno de liberación sostenida, para el tratamiento de esclerosis lateral amiotrófica.
MX2019011905A MX2019011905A (es) 2011-03-01 2014-09-02 Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013010044A MX360871B (es) 2011-03-01 2012-03-01 Nuevas composiciones para tratar trastornos neurológicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019011905A MX2019011905A (es) 2011-03-01 2014-09-02 Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.

Country Status (17)

Country Link
EP (1) EP2680836B1 (es)
JP (1) JP6328428B2 (es)
KR (2) KR101918669B1 (es)
CN (2) CN103608007A (es)
AU (1) AU2012222348B2 (es)
BR (1) BR112013022102A2 (es)
CA (1) CA2828763C (es)
DK (1) DK2819664T3 (es)
EA (1) EA032881B1 (es)
ES (2) ES2690490T3 (es)
HK (2) HK1245650A1 (es)
IL (2) IL228176A (es)
MX (3) MX360871B (es)
SG (2) SG192970A1 (es)
UA (2) UA115968C2 (es)
WO (2) WO2012117073A2 (es)
ZA (2) ZA201306038B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303562A1 (en) * 2010-12-02 2013-11-14 Massachusetts Institute Of Technology Chemical and rnai suppressors of neurotoxicity in huntington's disease
DK2560631T3 (da) 2011-03-01 2014-02-10 Pharnext Baclofen- og acamprosat-baseret af neurologiske forstyrrelser
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US9867837B2 (en) * 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
UA115968C2 (uk) * 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
AU2013224959B2 (en) * 2012-03-01 2017-12-07 Pharnext New compositions for treating amyotrophic lateral sclerosis
RS56175B1 (sr) * 2012-03-01 2017-11-30 Pharnext Nove kompozicije za lečenje amiotrofične lateralne skleroze
EP2705843A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
EP2705841A1 (en) * 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2014145874A1 (en) * 2013-03-15 2014-09-18 University Of Iowa Research Foundation Therapeutic methods
US9789072B2 (en) 2013-06-19 2017-10-17 Som Innovation Biotech, S.L. Therapeutic agents for use in the propylaxis and/or treatment of hyperkinetic movement disorders
MX2016006678A (es) * 2013-11-22 2016-09-13 Genzyme Corp Nuevos metodos para tratar enfermedades neurodegenerativas.
AU2015217796B2 (en) 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
JP6688295B2 (ja) * 2014-10-15 2020-04-28 オリオン コーポレーション 運動ニューロン病（例えばａｌｓ）の治療における使用のためのレボシメンダン
ES2751300T3 (es) 2014-11-21 2020-03-31 Biohaven Therapeutics Ltd Formulación sublingual de riluzol
JP6879560B2 (ja) * 2015-12-29 2021-06-02 国立大学法人京都大学 アルツハイマー病の予防及び／又は治療剤
AU2017216288B2 (en) * 2016-02-05 2022-06-02 Pharnext Novel combinatorial therapies of neurological disorders
CN110944639A (zh) * 2017-06-28 2020-03-31 国立大学法人京都大学 用于预防和/或治疗阿尔茨海默病的药剂
US10322114B2 (en) * 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
KR20250048143A (ko) 2017-07-31 2025-04-07 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
CN110891564A (zh) 2017-07-31 2020-03-17 诺华股份有限公司 玛沃谷兰在减少酒精使用或在预防复用酒精中的用途
WO2019145523A1 (en) * 2018-01-29 2019-08-01 Pharnext Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
KR20200121495A (ko) 2019-04-16 2020-10-26 동아대학교 산학협력단 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
WO2021011421A1 (en) * 2019-07-12 2021-01-21 University Of South Florida Compositions and methods for treating alzheimers disease
WO2022054927A1 (ja) * 2020-09-11 2022-03-17 国立大学法人大阪大学 オートファジーを活性化するための組成物
KR102866848B1 (ko) * 2022-04-07 2025-10-02 주식회사 미토스테라퓨틱스 설폰아미드계 화합물을 포함하는 근육질환 개선, 치료 또는 예방용 조성물
EP4257139B1 (en) * 2022-04-07 2025-06-25 Mitos Therapeutics Inc. Composition for improving, preventing or treating muscular disorders comprising sulfonamide-based compounds
CN117323305B (zh) * 2023-11-07 2024-06-07 杭州沐源生物医药科技有限公司 溴隐亭片剂及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742054A (en) * 1982-11-23 1988-05-03 Naftchi Nosrat E Treatment of mammals suffering from damage to the central nervous system
CA2044853C (en) * 1990-07-19 2004-11-09 Susan A. Greenfield Method for treating parkinson's disease employing an atp-sensitive potassium channel blocker
DE4113820A1 (de) * 1991-04-27 1992-10-29 Boehringer Mannheim Gmbh Verwendung von torasemid zur behandlung von hirnoedemen
US5486530A (en) * 1991-04-27 1996-01-23 Boehringer Mannheim Gmbh Use of torasemide for the treatment of brain oedemas
FR2722989B1 (fr) * 1994-07-29 1997-05-30 Synthelabo Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
WO2005019163A2 (en) 2003-08-20 2005-03-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP1716115B1 (en) 2003-12-30 2013-02-27 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
CN101365451A (zh) * 2005-11-21 2009-02-11 阿拉巴马大学董事会 使用小分子化合物用于神经保护的方法
WO2008046014A1 (en) * 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
ES2365574T3 (es) 2007-01-11 2011-10-07 Xenoport, Inc. Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento.
WO2009000406A1 (en) * 2007-06-22 2008-12-31 Bayer Healthcare Ag Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
US20090082464A1 (en) 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033054A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009052191A1 (en) 2007-10-15 2009-04-23 Xenoport, Inc. Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200936123A (en) 2007-11-06 2009-09-01 Xenoport Inc Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
LT2282778T (lt) * 2008-04-29 2017-06-26 Pharnext Nauji terapijos būdai, gydant alzheimerio ligą ir susijusius sutrikimus per angiogenezės moduliaciją
CA2722295C (en) * 2008-04-29 2019-01-15 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
CN102065897B (zh) * 2008-04-29 2013-11-13 法奈科斯公司 基于磺胺异噁唑的组合物用于制备治疗阿茨海默病的药物的应用
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US20120004225A1 (en) * 2009-01-22 2012-01-05 Neurotherapeutics Pharma, Inc. Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use
JP2012519212A (ja) 2009-03-03 2012-08-23 ゼノポート，インコーポレイティド Ｒ−バクロフェンプロドラッグの持効性放出経口投与形
US8344028B2 (en) 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
JP5886742B2 (ja) * 2009-07-24 2016-03-16 ウォルフガング・ミューラーＷｏｌｆｇａｎｇ Ｍｕｅｌｌｅｒ 内側側頭葉てんかん（ｔｌｅ）の処置及び可能性を防止／減少させる方法
CN101632665B (zh) * 2009-09-01 2011-08-17 严洁 一种托拉塞米口服药物组合物
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
UA115968C2 (uk) * 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
DK2560631T3 (da) * 2011-03-01 2014-02-10 Pharnext Baclofen- og acamprosat-baseret af neurologiske forstyrrelser

Also Published As

Publication number Publication date
MX373763B (es) 2020-03-24
SG192970A1 (en) 2013-09-30
BR112013022102A2 (pt) 2018-06-26
AU2012222348B2 (en) 2017-05-25
ZA201306038B (en) 2014-10-29
HK1245650A1 (en) 2018-08-31
DK2819664T3 (en) 2017-08-28
CA2828763C (en) 2020-07-21
JP2014506909A (ja) 2014-03-20
EP2680836B1 (en) 2018-06-13
EA201300975A1 (ru) 2014-02-28
WO2013127917A1 (en) 2013-09-06
SG11201405336VA (en) 2014-09-26
IL228176A (en) 2017-10-31
MX2019011905A (es) 2019-11-25
UA113165C2 (xx) 2016-12-26
ZA201406913B (en) 2016-03-30
MX360871B (es) 2018-11-16
NZ614267A (en) 2015-07-31
IL234023A0 (en) 2014-09-30
KR20140041457A (ko) 2014-04-04
ES2635872T3 (es) 2017-10-05
EP2680836A2 (en) 2014-01-08
KR101918669B1 (ko) 2018-11-15
CN103608007A (zh) 2014-02-26
MX2013010044A (es) 2014-02-17
IL234023B (en) 2018-10-31
JP6328428B2 (ja) 2018-05-23
WO2012117073A2 (en) 2012-09-07
ES2690490T3 (es) 2018-11-21
CA2828763A1 (en) 2012-09-07
EA032881B1 (ru) 2019-07-31
WO2012117073A3 (en) 2013-01-10
AU2012222348A1 (en) 2013-09-05
HK1258223A1 (en) 2019-11-08
KR20150002642A (ko) 2015-01-07
KR102014883B1 (ko) 2019-10-21
UA115968C2 (uk) 2018-01-25
CN108420819A (zh) 2018-08-21

Similar Documents

Publication Publication Date Title
MX2014010481A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
PH12013502623A1 (en) Metalloenzyme inhibitor compounds
PH12013502622A1 (en) Metalloenzyme inhibitor compounds
PH12013502624A1 (en) Metalloenzyme inhibitor compounds
PH12015502075B1 (en) Treatment of cataplexy
IN2014MN01378A (es)
MX391043B (es) Formulaciones de anticuerpo y metodos.
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
MX2015006337A (es) Metodos y composiciones para tratar enfermedades neurodegenerativas.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
IN2014DN00254A (es)
MX2013014488A (es) Metodos y composiciones para tratar el cancer cerebral.
EA201491581A1 (ru) Везикулярные композиции
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
MX2013002111A (es) Metodos y composiciones para el tratamiento de metastasis del cancer.
MX2014011473A (es) Procedimientos y composiciones de tratamiento de enfermedades vasculares arterioscleroticas.
IN2014DN07989A (es)
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
BR112015003815A2 (pt) métodos e composições para o tratamento de uma condição genética
TN2013000114A1 (en) Methods and compositions for treating lung cancer
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders

Legal Events

Date Code Title Description
FG Grant or registration